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TRAMP-C1 cells epididymal fat extracts from high-fat diet-fed obese mice stimulate androgen-independent
cell growth more signiﬁcantly than those from low-fat diet-fed lean mice or genetically obese leptin-
deﬁcient ob/ob mice in correlation with leptin concentrations. This result suggests that obesity promotes
androgen-independent prostate cancer cell growth via adipose leptin. We have reported that added leptin
stimulates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase (JNK).
As with JNK, signal transducer and activator of transcription 3 (STAT3) and Akt are implicated in androgen-
independent prostate cancer. In this study, we identify novel interaction of these three molecules in leptin-
stimulated androgen-independent cell proliferation. Leptin activates JNK, STAT3 and Akt in a biphasic
manner with a similar time-course. Pharmacological JNK inhibition suppresses leptin-stimulated DNA
binding activity, as well as Ser-727 phosphorylation, of STAT3. Since JNK upregulates STAT3 activity via Ser-
727 phosphorylation, JNK mediates leptin-stimulated STAT3 activation through Ser-727 phosphorylation.
Moreover, JNK inhibition impairs leptin-stimulated Ser-473 phosphorylation of Akt that is required for its
activation. Thus, JNK is involved in leptin-stimulated Akt activation. These ﬁndings together indicate that JNK
mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via STAT3 and Akt.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionProstate cancer is the second leading cause of cancer death among
American men. Development of androgen independence by cancer
cells is a fatal event during the natural history of the disease. Thus, the
molecular basis of androgen-independent prostate cancer (AIPC)
needs to be clariﬁed to develop cures and preventives for reducing
prostate cancer mortality.
Extensive evidence indicates that obesity, another serious health
problem, is associated with aggressive progression and mortality of
prostate cancer [1–5] though it appears to reduce the risk of non-
aggressive disease [4–6]. It is interesting to note that abdominalte cancer; IGF-I, insulin-like
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Adipocytes secrete various factors, including cytokines, growth factors
and hormones [8]. We have demonstrated that conditioned medium
from adipocyte culture augments AIPC cell proliferation [9]. This
ﬁnding indicates that adipose factors stimulate AIPC cell growth.
Leptin is one of the major adipose cytokines controlling body
weight homeostasis and insulin secretion [10,11]. A recessive muta-
tion in the leptin (obese, ob) gene causes obesity and type II diabetes
mellitus [12]. Plasma leptin levels correlate with total amounts of
body fat [13]. Furthermore, consistent with the fact that over-
expressing leptin genetic polymorphism is related to prostate cancer
[14], circulating leptin levels are associated with prostate cancer risk
[15–17] although some controversies exist [18–20]. Our previous
study has shown that prostate cancer cells express functional forms of
the leptin receptor and that leptin stimulates cell proliferation in AIPC
DU145 and PC-3 cells but not in androgen-dependent LNCaP-FGC cells
[9]. Leptin has also been demonstrated to mediate cell survival [21]
and migration [22] in AIPC cells. Intriguingly, leptin interacts with
other adipose cytokines insulin-like growth factor-I (IGF-I) and
interleukin-6 (IL-6) whose levels increase in obesity to stimulate
AIPC cell growth [9] whereas adiponectin, an adipose cytokine that
decreases in obesity, competes with leptin and IGF-I to inhibit AIPC
cell growth [23]. These observations suggest that adipose cytokines
are mediators between obesity and AIPC.
Fig. 1. Adipose leptin mediates cell proliferation in androgen-independent TRAMP-C1 prostate cancer cells that express leptin receptor. (A) mRNA expression of the two signaling-
competent leptin receptor isoforms muOB-Ra and muOB-Rbwas proﬁled in TRAMP-C1 cells. RT-PCR analysis identiﬁed expression of these isoforms with primers that detect each of
them speciﬁcally (muOB-Ra and muOB-Rb). PCR also ampliﬁed the common extracellular portion of the two isoforms (muOB-R). GAPDH served as a control. Presented are the
reproducible results from one of the four repeated experiments. The experiment was performed using three independently prepared samples (samples 1, 2 and 3): three PCR were
carried out simultaneously with each primer set, and PCR products were analyzed on the same gel. Three PCR showed consistent results with all primer sets. (B) TRAMP-C1 cells
were serum-starved for 48 h and stimulated with DHTor leptin at indicated concentrations for 20 h. [3H] thymidine incorporationwas measured during the last 5 h. Ethanol (Et) was
used as a vehicle control for DHT. Values represent the mean±SD of quadruplicate samples of a representative experiment. ⁎Pb 0.0005 versus the controls (open bars). (C) Fat
extracts were prepared from low-fat (Low) and high-fat (High) diet-fed male C57BL/6J mice, as well as regular diet-fed ob/ob mice (ob/ob), as described in Materials and methods.
TRAMP-C1 cells were deprived of serum for 24 h and treated for 5 days with these fat extracts using serum-free medium as a control. Cell viability was measured by the enzymatic
reduction of MTT (OD 550-670 nm) during the last 3 h. Values represent the mean±SD of quadruplicate samples of a representative experiment. ⁎Pb 0.01, ⁎⁎Pb 0.0005. (D) Serum-
starved TRAMP-C1 cells were incubated for 5 days with the control serum-free medium (open bars) or fat extracts from high-fat diet-fed male C57BL/6J mice (solid bars) in the
absence and presence of indicated concentrations of anti-leptin neutralizing antibody or non-speciﬁc mouse IgG; and cell viability was evaluated by the MTT assay. Values represent
the mean±SD of quadruplicate samples of a representative experiment. ⁎P= 0.002. (E) Conditioned mediumwas prepared from in vitro differentiated human primary adipocytes as
described before [9]. Serum-deprived DU145 cells were treated for 20 h with the control serum-free medium (open bars) or adipocyte condition medium (solid bars) in the absence
and presence of anti-leptin neutralizing antibody or non-speciﬁc mouse IgG at indicated concentrations. [3H] thymidine incorporation was measured during the last 5 h. Values
represent the mean±SD of quadruplicate samples of a representative experiment. ⁎Pb 0.02.
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signaling pathways upon binding to its cell-surface receptor. Several
splice variants of leptin receptor have been identiﬁed in mice (muOB-
Ra, b, c, d and e) [24] and humans (huOB-R and huB219.1 to huB219.3)
[25]. Only the full-length (muOB-Rb/huOB-R) and the second longest
(muOB-Ra/huB219.3) isoforms have been shown to mediate signal
transduction. These two isoforms demonstrate divergent signaling
capability: OB-Rb/OB-R mediates activation of both signal transducer
and activator of transcription 3 (STAT3) and extracellular regulating
kinase (ERK) 1/2 pathways while muOB-Ra/huB219.3 activates ERK1/2
but not STAT3 [26-28]. In addition, leptin is potent to activate such
other signaling pathways as the phosphatidylinositol-3 kinase (PI3K)
[29] and c-Jun NH2-terminal kinase (JNK) pathways [9,30].
JNK is a Ser/Thr kinase that constitutes one of the mammalian
mitogen-activated protein kinase families. Upon activation JNK
translocates to the nucleus, and phosphorylates and activatestranscription factors including activator protein-1 components,
c-Jun and activating transcription factor-2 to mediate various cellular
processes such as cell proliferation, cell survival, apoptosis and
malignant transformation [31]. JNK has been shown to be involved
in cell proliferation and survival in PC-3 cells in vitro [32] and PC-3
xenograft growth in vivo [33]. Furthermore, we have recently reported
that JNK is activated by leptin and required for leptin-stimulated
androgen-independent cell proliferation in DU145 and PC-3 cells [9].
STAT3 is an oncogenic transcription factor that mediates cellular
events including cell transformation, proliferation, survival and
migration [34]. Cytokines, such as leptin and IL-6, regulate STAT3
activation through phosphorylation at Tyr-705 and Ser-727 in the C-
terminus [34]. Upon ligand binding, cytokine receptors mediate STAT3
phosphorylation at Tyr-705 via receptor-associated Janus kinase (JAK).
Tyr-705 phosphorylation allows STAT3 to dimerize, translocate to the
nucleus and activate transcription from target gene promoters
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phosphorylation, Ser-727 phosphorylation occurs in the nucleus.
Ser-727 phosphorylation is mediated by Ser/Thr kinases including JNK
[36,37] and required for maximum, sustained STAT3 activation that is
crucial in cancer pathogenesis [34]. Constitutive STAT3 activation is
observed in primary prostate adenocarcinomamore prominently than
non-malignant prostate glands [38]. Furthermore, levels of STAT3
activation in tumor cells correlate with higher malignancy based on
Gleason scores [39]. Moreover, inhibition of constitutive STAT3
activation causes cell growth arrest and apoptosis in DU145 cells,
indicating that STAT3 is implicated in cell proliferation and survival in
AIPC cells [39]. Although leptin has been demonstrated to induce
STAT3 activation in several cell types, leptin-mediated STAT3 activa-
tion has not been reported in prostate cancer cells.
PI3K is a lipid kinase that phosphorylates inositol ring 3′-OH group
in inositol phospholipids to produce phosphatidylinositol-3,4,5-
triphospate (PIP3), leading to Akt, a Ser/Thr kinase, activation through
phosphorylation at Thr-308 and Ser-473 via 3′-phosphoinositide-
dependent protein kinases (PDKs) [40]. This PI3K-Akt pathway
controls cellular activities such as proliferation, survival, malignant
transformation, migration and morphogenesis [40]. Elevated Akt
activation is detected in human prostate cancer specimens including
almost all prostate intraepithelial neoplasia and invasive cancer
samples; and activation levels correlate with higher malignancy
[41]. Furthermore, the PI3K-Akt pathway mediates the development
and progression of AIPC [42–44]. In addition, the PI3 kinase-Akt
pathway has been reported to mediate AIPC cell migration in vitro
[22]. The PI3K-Akt pathway can be activated through multiple
mechanisms in cancer cells. Phosphatase and tensin homologue
deleted on chromosome 10 (PTEN), a phosphatase that depho-
sphorylates PIP3 to negatively regulate PI3K signaling, is frequently
mutated in prostate cancer, resulting in constitutive Akt activation in
cancer cells [41]. Paracrine and/or autocrine cytokines and growth
factors, such as IGF-I [45], can also activate the PI3K-Akt pathway.
Leptin has been shown to induce Akt activation during cell prolifera-
tion in DU145 cells that express wild-type PTEN [21].
In this study, we conﬁrm the crucial role of adipose leptin in
obesity-stimulated AIPC cell growth using the in vitro reconstitution
system in which mouse AIPC TRAMP-C1 cells are treated with
epididymal fat extracts from high-fat diet-fed obese and low-fat
diet-fed lean C57BL/6J mice and genetically obese leptin-deﬁcient ob/
ob mice. Furthermore, we demonstrate that JNK mediates leptin-
stimulated AIPC cell proliferation through STAT3 and Akt in DU145
cells. We also show that leptin activates JNK, STAT3 and Akt in not only
DU145 but also TRAMP-C1 cells.
2. Materials and methods
2.1. Materials
Recombinant human leptin, IL-6 and IGF-I, and anti-leptin
neutralizing antibody were purchased from R & D Systems Inc.
(Minneapolis, MN). SP600125 and LY294002 were bought from Tocris
Cookson, Inc. (Ellisville, MO). The stress-activated protein kinase/JNK
assay kit, anti-JNK, -c-Jun, -phospho-c-Jun (Ser-63), -phospho-c-Jun
(Ser-73), -STAT3, -phospho-STAT3 (Tyr-705), -phospho-STAT3 (Ser-
727) and -phospho-Akt (Ser-473) rabbit polyclonal antibodies, and
immobilized anti-Akt (1G1) mouse monoclonal antibody were from
Cell Signaling Technology, Inc. (Beverly, MA). Anti-STAT3 rabbit
polyclonal antibody for the electromobility shift assay (EMSA) was
obtained from Chemicon International (Temecula, CA). Anti-Akt rabbit
polyclonal antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mouse monoclonal antibody was a product of AbD Serotec
(Oxford, UK). The Mouse and Rat Leptin ELISA kit was bought from
BioVendor Laboratory Medicine, Inc. (Modrice, Czech Republic).C57BL/6J and ob/ob mice were obtained from Jackson laboratory
(Bar Harbor, ME). High-fat (58 kcal% fat, 5.55 kcal/g) and low-fat (11
kcal% fat, 4.07 kcal/g) diets were from Research Diets, Inc. (New
Brunswick, NJ).
2.2. Prostate cancer cells and culture conditions
Human prostate cancer cell line DU145 and mouse prostate cancer
cell line TRAMP-C1 were purchased from the American Type Culture
Collection (Manassas, VA). DU145 cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) plus 100 units/ml penicillin and 100 μg/ml
streptomycin. TRAMP-C1 cells were grown in DMEM containing 5%
FBS, 5% Nu-Serum IV, 100 units/ml penicillin, 100 μg/ml streptomycin,
0.005 mg/ml bovine insulin and 10 nM dehydroisoandrosterone,
according to a previous report [46]. All cultures were maintained at
37 °C in a 5 % CO2 atmosphere.
2.3. Reverse transcriptase (RT)-PCR analysis for leptin receptor isoforms
Seventy percent conﬂuent TRAMP-C1 cells were deprived of serum
for 24 h, and total RNA was prepared using the TRIZOL standard
technique. cDNA was generated from 1 μg of total RNA and subjected
to PCR analysis with primers amplifying each of the muOB-Ra and
muOB-Rb isoforms speciﬁcally, as well as their common extracellular
domain (muOB-R), following previous reports with some modiﬁca-
tions [47,48]. The reaction mixture for muOB and muOB-Ra ampliﬁca-
tion contained 5 % of the cDNA product, 10 mM Tris–HCl (pH 9),
50 mM KCl, 0.01% Triton X-100, 5 μM each primer, 200 μM dNTP
(Roche Applied Science), 1.5 mM MgCl2 and 1.5 U Taq polymerase
(Invitrogen), in a ﬁnal volume of 20 μl. The reactionmixture formuOB-
Rb ampliﬁcation had the same composition except that each primer
concentration was reduced to 1 μM. PCR for muOB and muOB-Rb was
performedwith an initial denaturing at 94 °C for 4min, followed by 35
cycles consisting of denaturing at 94 °C for 1 min, annealing at 55 °C
for 1 min, and extending at 72 °C for 1 min. PCR for muOB-Ra was
carried out under the same condition except for changing the
annealing temperature to 54 °C. The following forward and reverse
primers were used for leptin receptor ampliﬁcation: muOB-R (5′-CAG
ATT CGA TAT GGC TTA ATG GG-3′ and 5′-GTT AAA ATT CAC AAG GGA
AGC G-3′) [47], muOB-Ra (5′-ACA CTG TTA ATT TCA CAC CAG AG-3′
and 5′-AGT CAT TCA AAC CAT TAG TTT AGG-3′) [47], and muOB-Rb
(5′-ACA CTG TTA ATT TCA CAC CAG AG-3′ and 5′-TGG ATA AAC CCT
TGC TCT TCA-3′) [48]. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was employed as an internal standard. Forward and reverse
primers utilized for GAPDH ampliﬁcation were 5′-TGA AGG TCG GTG
TCA ACG GAT TTG GC-3′ and 5′-CAT GTA GGC CAT GAG GTC CAC CAC-
3′, and PCR was performed as described before [9]. PCR for muOB-R,
muOB-Ra, muOB-Rb and GAPDH generated products of 473, 237, 447
and 1000 bp, respectively. PCR products were separated by electro-
phoresis on 2 % agarose gels with ethidium bromide staining. All
experiments were repeated at least four times, each including three
independently prepared samples.
2.4. Preparation of fat extracts from mice
Three-week-oldmale C57BL/6J micewere placed on a low-or high-
fat diet (n= 9 each) and continued to be fed ad libitum the same diet
until sacriﬁced at 15 weeks of age. Immediately after euthanization by
CO2 asphyxiation, mice were weighed; and epididymal fat pads were
harvested, weighed and kept frozen at −80 °C until further processed.
For fat extract preparation, epididymal fat tissue (0.4 g) from each
mouse was minced extensively with surgical scissors and incubated
for 24 h in 10 ml of phenol red-free DMEM supplemented with 2.5 μg/
ml fungizone, 100 units/ml penicillin, 100 μg/ml streptomycin, 0.11 g/l
sodium pyruvate, and 0.584 g/l L-glutamine. The medium alone
Fig. 2. Leptin activates the JNK-c-Jun pathway biphasically in androgen-independent
DU145 prostate cancer cells. DU145 cells were serum-deprived for 24 h and incubated
in serum-free medium (lanes 1, 8, and 13) or the serum-free medium containing
12.5 μg/ml leptin (lanes 2–7, 9–12, and 14–18) for indicated periods. (A) Cell lysates
(250 μg protein) were subjected to the in vitro JNK assay with N-terminal c-Jun fusion
protein as a substrate. Phosphorylation of the substrate protein on Ser-63 was detected
by Western blot analysis using the speciﬁc antibody (Substrate (Ser-63)). To assess total
JNK protein levels, cell lysates (50 μg protein) were applied to Western blot analysis
using anti-JNK antibody that detects both active and inactive forms of JNK (p54 JNK and
p46 JNK). Membranes probedwith this antibody were stripped and re-probedwith anti-
GAPDH antibody to normalize variations in sample loading (GAPDH). (B) Cell lysates
(50 μg protein) were analyzed by Western blotting. c-Jun phosphorylation at Ser-63
and-73 was assessed using anti-phospho-c-Jun (Ser-63) and (Ser-73) antibodies (p-c-
Jun (Ser-63) and p-c-Jun (Ser-73)). To determine total c-Jun protein levels, membranes
probes with these antibodies were stripped and re-probed with anti-c-Jun antibody
that recognizes both phosphorylated and non-phosphorylated forms of c-Jun (c-Jun).
The same membranes were stripped again and re-hybridized with anti-GAPDH
antibody to normalize variations in sample loading (GAPDH). In some gels, a lane is
removed and the remaining lanes are spliced together. Such alterations are indicated by
leaving a white line between the gel pieces.
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dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
and ELISA described below. The conditioned medium (referred to as a
fat extract) was then collected, cleared by centrifugation to remove
tissue debris and stored at −80 °C until use. Fat extracts from ob/ob
mice were prepared following the same procedure except for feeding
mice on a regular diet.
2.5. Preparation of human adipocyte conditioned medium
Human primary adipocytes were purchased from BioWhittaker
Inc. (Walkersville, MD) and differentiated into mature adipocytes in
vitro; and the conditioned medium was prepared as previously
described [9].
2.6. MTT assay
TRAMP-C1 cells (0.5×103/well) were seeded in 96-well plates,
followed by serum starvation for 24 h. Cells were then grown in fat
extracts or the control mock-incubated medium for 5 days and
subjected to MTT assays as previously reported [9]. Values were
shown as means±SD of quadruplicated determinations of a repre-
sentative experiment (repeated three times).
2.7. Measurement of leptin concentrations
Leptin concentrations of fat extracts were measured by the Mouse
and Rat Leptin ELISA kit according to the manufacturer's protocol.
2.8. Cell lysate preparation
DU145 and TRAMP-C1 cells were seeded into 10-cm plates and
grown to a 70% conﬂuent state. In experiments proﬁling the time-
dependent effect of cytokine treatment on signal transduction, cells
were starved in serum-free medium for 24 h and treated with
cytokine for indicated periods. Cytokine treatment was carried out
by changing the starvation medium with fresh serum-free medium
containing 12.5 μg/ml leptin, 100 ng/ml IL-6 or 100 ng/ml IGF-I. In
experiments testing the effect of JNK or PI3K inhibition on cytokine-
mediated signal transduction, following serum starvation cells were
pretreated with 10 μM SP600125 or 5 μM LY294002 for 30 min
before cytokine treatment. Pretreatment was performed by replacing
the starvation medium with fresh serum-free medium with and
without Me2SO (vehicle control) or each of the inhibitors. One
hundred-fold concentrated leptin, IL-6 or IGF-I solution was then
added to cultures to make a ﬁnal concentration of 12.5 μg/ml,
100 ng/ml or 100 ng/ml, respectively. We tested the effect of vehicle
solutions for these cytokines (20 mM Tris–HCl, pH 8.0 for leptin;
phosphate-buffered saline containing 0.1% bovine serum albumin for
IL-6 and IGF-I) on JNK, STAT3 and Akt activation, and found noTable 1
Comparison of body weight, fat weight and leptin concentrations of fat extracts among
high-and low-fat diet-fed C57BL/6J mice and ob/ob mice. Body weight and epididymal
fat weight were measured at sacriﬁce
Control Low High ob /ob
mice
P-value
(Low:High)
P-value
(High:ob/ob)
Body weight (g) N/A 27.79
±2.01
37.02
±3.80
42.74
±2.02
0.000002 0.034834
Fat weight (g) N/A 0.80
±0.18
2.25
±0.40
4.01
±0.25
b10–6 0.000038
Leptin concentration of
fat extract (ng/ml)
1.38
±0.01
10.56
±2.73
15.18
±5.03
6.50
±0.60
0.017250 0.016082
Fat extracts were prepared from epididymal fat pads as described in Materials and
methods, and leptin concentrations were determined by ELISA.
N/A, not applicable.differential effect with and without addition of either vehicle
solution (data not shown). Therefore, controls for cytokine treatment
were sampled without adding any vehicle solution. Cell lysates were
prepared as previously described [9], frozen on dry ice and stored at
−80 °C until use.
2.9. Western blot analysis of c-Jun, STAT3 and Akt
To measure phosphorylation states of c-Jun and STAT3, cell lysates
containing 50 μg of protein were subjected to Western blot analysis
using anti-phospho-c-Jun (Ser-63 and -73) and-phospho-STAT3 (Tyr-
705 and Ser-727) antibodies as described before [9,49]. Membranes
probed with these antibodies were stripped and re-probed with anti-
c-Jun and -STAT3 antibodies to determine c-Jun and STAT3 protein
levels. The same membranes were stripped again and re-probed with
anti-GAPDH antibody for normalizing variations in sample loading. To
assess Akt phosphorylation at Ser-473, phosphorylated Akt was
immunoprecipitated from cell lysates (1 mg protein) with anti-
immobilized anti-Akt (1G1) monoclonal antibody and detected by
Western blot analysis using anti-phospho-Akt (Ser-473) polyclonal
antibody. Total protein levels of Akt were determined in cell lysates by
Fig. 3. Leptin biphasically stimulates the DNA binding activity and Tyr-705 and Ser-727 phosphorylation of STAT3 in androgen-independent DU145 prostate cancer cells. Following
24-h serum starvation, DU145 cells were incubated in serum-free medium in the absence (lanes 1, 8, 13, and 19) and presence (lanes 2–7, 9–12,14–18, and 20–22) of 12.5 μg/ml leptin
for indicated periods. (A) To assay STAT3 DNA binding activity, cell lysates (10 μg protein) were subjected to EMSAusing 32P-end-labeled M67-SIE as a probe. The STAT3–DNA complex
was conﬁrmed by the supershift assay using anti-STAT3 antibody (lanes 19–22). A lane is removed from one of the gels, and the remaining lanes are spliced together. This alteration is
indicated by putting a white line between the gel pieces. STAT3, STAT3–DNA complex; STAT3 Ab, anti-STAT3 antibody; SS, STAT3–DNA complex supershifted by the anti-STAT3
antibody; NS, non-speciﬁc. (B) Cell lysates (50 μg protein) were applied to Western blot analysis. STAT3 phosphorylation at Tyr-705 and Ser-727 was assessed with anti-phospho-
STAT3 (Tyr-705) and (Ser-727) antibodies (p-STAT3 (Tyr-705) and p-STAT3 (Ser-727)). To determine total amounts of STAT3 protein, membranes hybridized with these antibodies were
stripped and re-hybridized with anti-STAT3 antibody that detects both phosphorylated and non-phosphorylated forms of STAT3 (STAT3). The same membranes were stripped again
and re-hybridized with anti-GAPDH antibody to normalize variations in sample loading (GAPDH).
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with anti-Akt antibody were stripped and re-hybridized with anti-
GAPDH antibody to normalize variations in sample loading. All
experiments were repeated at least three times, and representative
results were presented.
2.10. In vitro JNK assay
Cell lysates (250 μg protein) were applied to the in vitro JNK assay
utilizing the stress-activated protein kinase/JNK assay kit following
the manufacturer's instructions with some modiﬁcations as reported
before [9]. Brieﬂy, JNK was precipitated in cell lysates with
glutathione-Sepharose beads immobilized by a recombinant fusion
protein of the c-Jun N-terminus (1–89) and glutathione S-transferase
as a JNK substrate. The kinase reaction was then carried out in the
presence of 200 μMATP at 30 °C for 30min. Substrate phosphorylation
at Ser-63 was determined by Western blot analysis using anti-
phospho-c-Jun (Ser-63) polyclonal antibody. Cell lysates were also
assessed for JNK protein levels by Western blot analysis with anti-JNK
antibody. Membranes probed with the anti-JNK antibody werestripped and re-probed with anti-GAPDH antibody to normalize
variations in sample loading. All results were representative of three
or more independent data sets.
2.11. EMSA
Cell lysates (10 μg protein) were subjected to EMSA with 32P-end-
labeled double-stranded oligonucleotide M67-SIE as a probe as
previously described [50]. Supershift assays were performed using
anti-STAT3 antibody to conﬁrm the STAT3–DNA complex.
2.12. Thymidine incorporation assay
DU145 (1.5×105/well) and TRAMP-C1 (1.0×105/well) cells were
seeded into 24-well plates, deprived of serum for 48 h, treated with
leptin or dihydrotestosterone (DHT) at indicated concentrations for
20 h, and subjected to thymidine incorporation assays as reported
previously [9]. DHT was used to determine whether TRAMP-C1 cells
are androgen-responsive. In experiments with PI3K inhibition, cells
were pretreated with 5 μM LY294002 for 30 min prior to leptin
Fig. 4. Leptin stimulates Akt phosphorylation at Ser-473 in a biphasic manner in
androgen-independent DU145 prostate cancer cells. DU145 cells were serum-deprived
for 24 h and incubated in serum-free medium in the absence (lanes 1, 8, and 13) and
presence (lanes 2–7, 9–12, and 14–18) of 12.5 μg/ml leptin for indicated periods. Akt
phosphorylated at Ser-473 was immunoprecipitated in cell lysates (1 mg protein) with
immobilized anti-Akt (1G1) antibody and detected by Western blot analysis using anti-
phospho-Akt (Ser-473) antibody (p-Akt (Ser-473)). To determine total levels of Akt
protein, cell lysates (50 μg protein) were applied toWestern blot analysis using anti-Akt
antibody that recognizes both phosphorylated and non-phosphorylated forms of Akt
(Akt). Membranes probed with this antibody were stripped and re-probed with anti-
GAPDH antibody to normalize variations in sample loading (GAPDH). In some gels, a
lane is removed and the remaining lanes are spliced together. Such alterations are
indicated by putting a white line between the gel pieces.
Fig. 5. JNK mediates the leptin-stimulated DNA binding activity and phosphorylation of
STAT3 in androgen-independent DU145 prostate cancer cells. Following 24-h serum
deprivation, DU145 cells were treated with 12.5 μg/ml leptin for 15 or 120 min or
100 ng/ml IL-6 for 15 min with and without pretreatment with Me2SO (vehicle control)
or 10 μM SP600125 (pharmacological JNK inhibitor) for 30 min. Cells without any
treatment (lanes 1, 7 and 13) and treated with Me2SO alone (lanes 2, 8 and 14) were
included as controls. (A) To assess STAT3 DNA binding activity, cell lysates (10 μg
protein) were subjected to EMSA with 32P-end-labeled M67-SIE as a probe. STAT3,
STAT3–DNA complex; NS, non-speciﬁc. (B) Cell lysates (50 μg protein) were analyzed by
Western blotting. STAT3 phosphorylation at Tyr-705 and Ser-727 was determined using
anti-phospho-STAT3 (Tyr-705) and (Ser-727) antibodies (p-STAT3 (Tyr-705) and p-STAT3
(Ser-727)). To measure total STAT3 protein levels, membranes hybridized with these
antibodies were stripped and re-hybridized with anti-STAT3 antibody that recognizes
both phosphorylated and non-phosphorylated forms of STAT3 (STAT3). The same
membranes were stripped again and re-hybridized with anti-GAPDH antibody to
normalize variations in sample loading (GAPDH).
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least three times. Values were reported as means±SD of quadrupli-
cated measurements of a representative experiment.
3. Results
3.1. Adipose leptin stimulates AIPC cell growth in obesity
Our previous study has demonstrated that added recombinant
leptin augments androgen-independent cell proliferation in human
prostate cancer DU145 and PC-3 cells [9]. However, it has not been
clear whether obesity stimulates AIPC cell growth through adipose
leptin. Here we address this question with a newly developed in vitro
system utilizing mouse prostate cancer cells and fat extracts.
RT-PCR analysis demonstrated that mouse prostate cancer TRAMP-
C1 cells, as well as human prostate cancer cells [9], expressed
signaling-competent leptin receptor isoforms (Fig. 1A). This result
suggests that leptin may mediate cell proliferation in TRAMP-C1
cells. We employed the thymidine incorporation assay to test this
hypothesis. As with DU145 and PC-3 cells [9] TRAMP-C1 cells
proliferated in response to added leptin but not DHT: leptin
stimulated cell proliferation in a dose-dependent manner at concen-
trations up to 12.5 μg/ml while DHT did not inﬂuence it at 0.1, 1, 10 or
100 nM (Fig. 1B). This ﬁnding allowed developing an in vitro
reconstitution system to investigate the effect of such adipose factors
as leptin contained in mouse epididymal fat extracts on androgen-
independent cell growth in TRAMP-C1 cells. To deﬁnewhether obesity
stimulates AIPC cell growth via adipose leptin, we employed the MTT
assay to compare the effect of fat extracts on TRAMP-C1 cell growth
among high-fat diet-fed obese and low-fat diet-fed lean male C57BL/
6J mice and genetically obese leptin-deﬁcient male ob/ob mice. As
shown in Table 1, the high-fat diet markedly increased body weight,
epididymal fat pad weight and fat extract leptin levels in C57BL/6J
males whereas the low-fat diet maintained them at low levels. Fat
extracts from high-fat diet-fed C57BL/6J males facilitated TRAMP-C1
cell growth more signiﬁcantly than those from low-fat diet-fed males
in correlation with leptin concentrations (Fig. 1C). In addition, fat
extracts from leptin-deﬁcient ob/ob males were remarkably less
stimulatory to cell growth than those from high-fat diet-fed C57BL/6J
males (Fig. 1C) although the former mice were more obese than the
latter (Table 1). These results indicate that obesity augments AIPC cellgrowth through adipose leptin. To further conﬁrm the involvement of
adipose leptin in AIPC cell growth, we neutralized leptin with anti-
leptin antibody in fat extracts from high-fat diet-fed mice to examine
the effect on fat extract-stimulated TRAMP-C1 cell growth. Addition of
5 μg/ml anti-leptin neutralizing antibody signiﬁcantly inhibited fat
extract-facilitated TRAMP-C1 cell growth while control non-speciﬁc
mouse IgG did not inﬂuence it (Fig. 1D), providing direct evidence for
leptin involvement. Moreover, the thymidine incorporation assay
showed that consistent with our previous report [9] conditioned
medium from in vitro differentiated human adipocytes stimulated
androgen-independent cell proliferation in DU145 cells and that anti-
leptin antibody, but not the control IgG, suppressed conditioned
Fig. 7. JNK is indispensable for leptin-stimulated Akt phosphorylation at Ser-473 in
androgen-independent DU145 prostate cancer cells. DU145 cells were deprived of
serum for 24 h and treated with 12.5 μg/ml leptin for 5 min or 4 h or 100 ng/ml IGF-I for
15minwith andwithout pretreatment withMe2SO (vehicle control) or 10 μMSP600125
(pharmacological JNK inhibitor) for 30 min. Cells without any treatment (lanes 1, 7 and
13) and treatedwithMe2SO alone (lanes 2, 8 and 14) were included as controls. Ser-473-
phosphorylated Akt was immunoprecipitated in cell lysates (1 mg protein) with
immobilized anti-Akt (1G1) antibody and detected by Western blot analysis using anti-
phospho-Akt (Ser-473) antibody (p-Akt (Ser-473)). To determine total levels of Akt
protein, cell lysates (50 μg protein) were subjected to Western blot analysis using anti-
Akt antibody that recognizes both phosphorylated and non-phosphorylated forms of
Akt (Akt). Membranes probed with this antibody were stripped and re-probed with
anti-GAPDH antibody to normalize variations in sample loading (GAPDH).
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25 μg/ml) (Fig. 1E). This observation suggests that adipose leptin
stimulates AIPC cell growth not only inmice but also in humans. These
results together lead to the conclusion that adipose leptin mediates
obesity-stimulated AIPC cell growth.
3.2. Leptin activates JNK, STAT3 and Akt in a biphasic manner during
AIPC cell proliferation
We have shown that leptin activates JNK rapidly in AIPC cells
within 15-min treatment and that this activation is required for leptin-
stimulated AIPC cell proliferation [9]. STAT3 [39] and Akt [42–44], as
well as JNK [9,32,33], play an important role in AIPC pathogenesis.
Leptin has been shown to be capable of activating each of these
molecules in various cell types [21,26–29]. However, there is no
evidence for simultaneous activation/interaction of the three mole-
cules by leptin in any cell types including AIPC cells. Both rapid and
persistent activation of these molecules are important in cancer
pathogenesis. Herewe treated DU145 cells with 12.5 μg/ml leptin over
extended periods (up to 48 h) to determine whether leptin stimulates
activation of JNK, STAT3 and Akt rapidly and/or persistently.
Consistent with our previous report [9], JNK activity was
constitutively detected at a low level and stimulated by leptin,
peaking at 15 min after addition of leptin and returning to the basal
level 45 min after (Fig. 2A). JNK was then re-activated starting at
75 min, and the second phase of activation sustained at least untilFig. 6. The PI3K-Akt pathway mediates leptin-stimulated androgen-independent cell
proliferation in DU145 cells. (A) Androgen-independent DU145 prostate cancer cells
were serum-starved for 24 h and treated with 12.5 μg/ml leptin for 5 min with and
without pretreatment with Me2SO (vehicle control) or 5 μM LY294002 (pharmacolo-
gical PI3K inhibitor) for 30 min. Cells without any treatment (lanes 1 and 2) and treated
with Me2SO alone (lanes 3 and 4) served as negative controls. Ser-473-phosphorylated
Akt was immunoprecipitated in cell lysates (1 mg protein) with immobilized anti-Akt
(1G1) antibody and assessed byWestern blot analysis using anti-phospho-Akt (Ser-473)
antibody (p-Akt (Ser-473)). To determine total Akt protein levels, cell lysates (50 μg
protein) were subjected to Western blot analysis using anti-Akt antibody that detects
both phosphorylated and non-phosphorylated forms of Akt (Akt). Membranes probed
with this antibody were stripped and re-probed with anti-GAPDH antibody to
normalize variations in sample loading (GAPDH). (B) After 48-h serum deprivation,
DU145 cells were incubated for 20 h in serum-free medium in the absence (open bars)
and presence (solid bars) of 12.5 μg/ml leptin with and without pretreatment with
Me2SO or 5 μMLY294002 for 30min. Cell proliferationwas measured by [3H] thymidine
incorporation during the last 5 h. Values represent the mean±SD of quadruplicate
samples of a representative experiment. ⁎Pb 0.005 versus the controls (open bars).after 24 h (Fig. 2A). JNK mediates c-Jun activation through Ser-63 and-
73 phosphorylation [31]. We proﬁled c-Jun phosphorylation at these
Ser residues in response to leptin. Leptin stimulated c-Jun phosphor-
ylation at both Ser residues in correlationwith JNK activation (Fig. 2B).
The DNA binding activity of STAT3 was constitutively observed in
DU145 cells as previously reported [39] and further stimulated by
leptin treatment in a biphasic fashion, peaking 15 min and 2–8 h after
leptin addition (Fig. 3A). This is the ﬁrst evidence for leptin-mediated
STAT3 activation in prostate cancer cells. STAT3 activation is regulated
through Tyr-705 and Ser-727 phosphorylation [34]. We found that
STAT3 was constitutively phosphorylated at these residues and that
leptin biphasically augmented STAT3 phosphorylation at both resi-
dues correlating to the DNA binding activity (Fig. 3B).
Phosphorylation at Ser-473 is required for Akt activation [40].
Leptin stimulated Ser-473 phosphorylation, peaking at 5 min and 4–
8 h after addition of leptin (Fig. 4). Thus, leptin activated Akt, as well as
JNK-c-Jun and STAT3, in a biphasic manner.
3.3. JNK mediates leptin-stimulated STAT3 DNA binding activity and
phosphorylation
JAK-mediated Tyr-705 phosphorylation is a cytosolic event
obligatory for STAT3 activation whereas Ser-727 phosphorylation
that occurs in the nucleus after Tyr-705 phosphorylation is required
for maximal, prolonged STAT3 activation [34]. JNK is potent to
regulate STAT3 activity through Ser-727 phosphorylation [37]. Since
leptin stimulates JNK and STAT3 in a biphasic fashion showing a
similar time-course in DU145 cells (Figs. 2 and 3), JNK may mediate
leptin-stimulated STAT3 activation via Ser-727 phosphorylation
during AIPC cell proliferation. To determine whether JNK is involved
in the ﬁrst and/or second phases of leptin-stimulated STAT3
activation, we examined the effect of pharmacological JNK inhibition
with 10 μM SP600125 on the DNA binding activity, as well as Ser-727
and Tyr-705 phosphorylation, of STAT3 after leptin treatment
(12.5 μg/ml) for 15 and 120 min. The SP600125 concentration
(10 μM) was chosen that completely blocks leptin-induced JNK
activation in DU145 cells [9]. JNK inhibition remarkably attenuated
leptin-stimulated DNA binding activity and Ser-727 phosphorylation
of STAT3 at both time points (Fig. 5A and B). These data suggest that
leptin stimulates STAT3 DNA binding activity through JNK-mediated
Fig. 8. Leptin activates JNK, STAT3 and Akt pathways in androgen-independent prostate cancer TRAMP-C1 cells. TRAMP-C1 cells were starved of serum for 24 h and stimulated with
12.5 μg/ml leptin for indicated periods. (A) Cell lysates were subjected to the in vitro JNK assay with N-terminal c-Jun fusion protein as a substrate (Substrate (Ser-63)) and Western
blot analysis using anti-phospho-c-Jun (Ser-63) and (Ser-73) antibodies (p-c-Jun (Ser-63) and p-c-Jun (Ser-73)). The membrane probed with anti-phospho-c-Jun (Ser-63) antibody
was stripped and re-probedwith anti-c-Jun antibody to normalize c-Jun phosphorylation to total c-Jun protein levels (c-Jun). (B) Left panel, Cell lysates were applied to EMSA to assess
STAT3 DNA binding activity using 32P-end-labeled M67-SIE as a probe. STAT3, STAT3–DNA complex. Right panel, STAT3 phosphorylation on Tyr-705 and Ser-727 was determined in
cell lysates byWestern blot analysis using anti-phospho-STAT3 (Tyr-705) and (Ser-727) antibodies (p-STAT3 (Tyr-705) and p-STAT3 (Ser-727)). To normalize STAT3 phosphorylation to
total STAT3 protein levels, the membrane hybridized with anti-phospho-STAT3 (Tyr-705) antibody was stripped and re-hybridized with anti-STAT3 antibody (STAT3). (C) Akt
phosphorylated at Ser-473 was immunoprecipitated with immobilized anti-Akt (1G1) antibody in cell lysates and analyzed by Western blotting using anti-phospho-Akt (Ser-473)
antibody (p-Akt (Ser-473)). To normalize Akt phosphorylation to total amounts of Akt protein, cell lysates were subjected to Western blot analysis with anti-Akt antibody (Akt).
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the ﬁrst phase of STAT3 activation and Ser-727 phosphorylation
partially but the second phase thoroughly. This observation suggests
that Ser-727 phosphorylation via JNK is essential for leptin-
stimulated, not rapid but sustained activation of STAT3 and that
the rapid, maximal activation involves both JNK-dependent and-
independent Ser phosphorylation. Furthermore, suppression of Ser-
727 phosphorylation was accompanied by a decrease in Tyr-705
phosphorylation (Fig. 5B). Therefore, JNK-mediated Ser-727 phos-
phorylation may augment STAT3 activity through stabilizing Tyr-705
phosphorylation. In addition, we tested the effect of SP600125 on IL-
6-mediated STAT3 DNA binding activity and phosphorylation. Unlike
leptin-mediated STAT3 activation, SP600125 pretreatment did not
signiﬁcantly suppress either DNA binding activity (Fig. 5A) or Ser-
727/Tyr-705 phosphorylation (Fig. 5B) of STAT3 in DU145 cells when
treated with 100 ng/ml IL-6 for 15 min. This result indicates that
SP600125 does not inhibit STAT3 activation in a non-speciﬁc fashion
and further conﬁrms the implication of JNK in leptin-stimulated
STAT3 activation.
3.4. Akt is implicated in leptin-stimulated AIPC cell proliferation
Since leptin stimulates Ser-473 phosphorylation of Akt during AIPC
cell proliferation (Fig. 4), Akt may mediate leptin-stimulated AIPC cell
proliferation. To conﬁrm this, we blocked activation of Akt by
pharmacologically inhibiting its upstream effector PI3K with
LY294002 and determined the effect on cell proliferation stimulated
by 12.5 μg/ml leptin in the absence of androgen. LY294002 completely
suppressed leptin-stimulated cell proliferation, as well as Akt
phosphorylation, at 5 μM (Fig. 6A and B). Thus, the PI3K-Akt pathway
mediates leptin-stimulated AIPC cell proliferation. In addition,
LY294002 inhibited both cell proliferation and Akt phosphorylationin leptin-untreated cells, indicating that the PI3K-Akt pathway is
important in the basal level of AIPC cell proliferation.
3.5. JNK mediates leptin-stimulated Akt activation
As with JNK and STAT3, Akt is biphasically activated by leptin (Fig.
4) and plays a crucial role in leptin-stimulated AIPC cell proliferation
(Fig. 6). Since JNKmediates leptin-stimulated STAT3 activation (Fig. 5),
JNKmay also be involved in leptin-stimulated Akt activation. To deﬁne
whether JNK mediates the ﬁrst and/or second phase of leptin-
stimulated Akt activation, we tested the effect of pharmacological
JNK inhibition on Ser-473 phosphorylation of Akt after treatment with
12.5 μg/ml leptin for 5 min and 4 h. JNK inhibition with 10 μM
SP600125 suppressed the ﬁrst phase of leptin-stimulated Akt
phosphorylation completely and the second phase partially (Fig. 7).
Thus, JNK is indispensable for rapid Akt activation by leptin while the
late phase of sustained activation implicates a JNK-independent, as
well as-dependent, mechanism. In addition, in contrast to leptin-
mediated Akt phosphorylation SP600125 pretreatment did not affect
Akt phosphorylation in DU145 cells when treated with 100 ng/ml IGF-
I for 15 min (Fig. 7). Therefore, SP600125 does not inhibit Akt
activation in a non-speciﬁc manner, further conﬁrming the involve-
ment of JNK in leptin-stimulated Akt activation.
3.6. Leptin activates JNK, STAT3 and Akt in not only DU145 but also
TRAMP-C1 cells
To conﬁrm whether leptin activates JNK, STAT3 and Akt pathways
not only in DU145 cells but also in other AIPC cells, we examined the
effect of short-term leptin treatment on activation of these pathways
in TRAMP-C1 cells. All the three pathways were constitutively
activated in TRAMP-C1 cells (Fig. 8). Treatment with 12.5 μg/ml leptin
Fig. 9. JNKmediates leptin-stimulated STAT3 DNA binding activity and phosphorylation,
as well as Akt phosphorylation, in androgen-independent TRAMP-C1 prostate cancer
cells. Following 24-h serum deprivation, TRAMP-C1 cells were treated with 12.5 μg/ml
leptin for 15 minwith and without pretreatment with Me2SO (vehicle control) or 10 μM
SP600125 (pharmacological JNK inhibitor) for 30min. Cells without any treatment (lane
1) and treated with Me2SO alone (lane 2) were included as controls. (A) To assess STAT3
DNA binding activity, cell lysates (10 μg protein) were subjected to EMSAwith 32P-end-
labeled M67-SIE as a probe. STAT3, STAT3–DNA complex; NS, non-speciﬁc. (B) Cell
lysates (50 μg protein) were analyzed by Western blotting. STAT3 phosphorylation at
Tyr-705 and Ser-727 was determined using anti-phospho-STAT3 (Tyr-705) and (Ser-
727) antibodies (p-STAT3 (Tyr-705) and p-STAT3 (Ser-727)). To measure total STAT3
protein levels, membranes hybridized with these antibodies were stripped and re-
hybridized with anti-STAT3 antibody that recognizes both phosphorylated and non-
phosphorylated forms of STAT3 (STAT3). The same membranes were stripped again and
re-hybridized with anti-GAPDH antibody to normalize variations in sample loading
(GAPDH). (C) TRAMP-C1 cells were deprived of serum for 24 h and treated with 12.5 μg/
ml leptin for 10 minwith and without pretreatment with Me2SO or 10 μM SP600125 for
30 min. Cells without any treatment (lane 1) and treated with Me2SO alone (lane 2)
were included as controls. Ser-473-phosphorylated Akt was immunoprecipitated in cell
lysates (1 mg protein) with immobilized anti-Akt (1G1) antibody and detected by
Western blot analysis using anti-phospho-Akt (Ser-473) antibody (p-Akt (Ser-473)). To
determine total levels of Akt protein, cell lysates (50 μg protein) were subjected to
Western blot analysis using anti-Akt antibody that recognizes both phosphorylated and
non-phosphorylated forms of Akt (Akt). Membranes probed with this antibody were
stripped and re-probed with anti-GAPDH antibody to normalize variations in sample
loading (GAPDH).
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Ser-63 and-73 (Fig. 8A). In addition, leptin augmented the DNA
binding activity and Tyr-705 and Ser-727 phosphorylation of STAT3
after 15-min treatment (Fig. 8B). Furthermore, Akt phosphorylation at
Ser-473 was rapidly up-regulated by leptin in a time-dependent
fashion, peaking at 10 min after leptin addition (Fig. 8C). Therefore,
TRAMP-C1 and DU145 cells exhibit similar activation proﬁles of JNK,
STAT3 and Akt pathways in response to leptin.
3.7. JNK mediates leptin-stimulated STAT3 and Akt activation in not only
DU145 but also TRAMP-C1 cells
Since leptin stimulates JNK, STAT3 and Akt in both TRAMP-C1 and
DU145 cells, JNK may be involved in leptin-mediated STAT3 and Akt
activation in TRAMP-C1, as well as DU145, cells. To conﬁrm this, we
ﬁrst examined the effect of JNK inhibitionwith 10 μMSP600125 on the
DNA binding activity and Ser-727 and Tyr-705 phosphorylation of
STAT3 in TRAMP-C1 cells when treated with 12.5 μg/ml leptin for
15 min. As observed in DU145 cells (Fig. 5A and B), SP600125
pretreatment remarkably attenuated leptin-stimulated DNA binding
activity (Fig. 9A), as well as Ser-727 and Tyr-705 phosphorylation (Fig.
9B), of STAT3. We then tested the effect of JNK inhibition on Akt
phosphorylation at Ser-473 in TRAMP-C1 cells when treated with
leptin for 10 min. JNK inhibition thoroughly blocked Akt phosphor-
ylation (Fig. 9C). Thus, JNK mediates leptin-stimulated STAT3 and Akt
activation in not only DU145 but also TRAMP-C1 cells, suggesting that
leptin-induced interaction of JNK, STAT3 and Akt may be a common
signaling event that mediates AIPC cell proliferation.
4. Discussion
AIPC is an advanced, lethal form of prostate cancer. Obesity is
associated with advanced prostate cancer [1–5]. Our recent study has
demonstrated that conditioned medium from human primary
adipocyte culture augments cell proliferation in human AIPC DU145
and PC-3 cells, indicating that adipose factors mediate AIPC cell
proliferation [9]. Leptin is a major adipose cytokine whose production
is signiﬁcantly increased in obesity [13]. We have reported that added
leptin stimulates androgen-independent cell proliferation in DU145
and PC-3 cells [9]. These facts together lead to a hypothesis: adipose
leptin increased in obesity facilitates AIPC cell growth.
In this study, we found that like DU145 and PC-3 cells mouse
prostate cancer TRAMP-C1 cells were androgen-independent and
proliferated in response to leptin (Fig. 1B). Taking advantage of this
ﬁnding, we developed the in vitro reconstitution system involving
TRAMP-C1 cells and epididymal fat extracts from obese and lean mice
to test the effect of adipose factors, including leptin, on AIPC cell
growth. This system is advantageous in that: (1) cytokines produced
by mouse adipose tissue are compatible with TRAMP-C1 cells so that
interaction of adipose cytokines with tumor cells can be investigated;
(2) the effect of experimentally induced obesity on adipose factor-
prostate cancer cell interaction can be evaluated. Using this system in
combinationwith high-and low-fat diet-fed C57BL/6J mice and leptin-
deﬁcient ob/ob mice, we showed that adipose leptin played a pivotal
role in obesity-stimulated AIPC cell growth (Table 1 and Fig. 1C).
Adipose factors could act on cancer cells in both endocrine and
paracrine manners: cancer cells would be exposed to paracrine
adipose factors when prostate tumors invade into retropubic fat pads
or metastasize to bonemarrow. It should be noted that concentrations
of exogenous leptin stimulatory to AIPC cell proliferation (100 ng/ml–
12.5 μg/ml in DU145 and PC-3 cells, 2–12.5 μg/ml in TRAMP-C1 cells)
[9] (Fig. 1B) are signiﬁcantly higher than leptin levels in circulation in
men (5–100 ng/ml) [13,51–53] or mouse fat extracts (10–15 ng/ml)
(Table 1). Our data show that other adipose cytokines such as IGF-I and
IL-6 sensitize AIPC cells to leptin [9]. Therefore, effective leptin
concentrations in vivo should be much lower than those required forleptin alone-stimulated AIPC cell proliferation in vitro. This is
supported by a report showing that 4–40 ng/ml leptin stimulates
DU145 and PC-3 cell proliferation in the presence of 10 % fetal bovine
serum [21]. In this study, we dared to use a high concentration of
leptin (12.5 μg/ml) in the absence of serum in order to analyze its pure
effect on signal transduction implicated in AIPC cell proliferation.
JNK is required for cell proliferation and survival in androgen-
independent PC-3 cells in vitro [32] and growth of PC-3 xenografts in
athymic mice [33]. STAT3 is crucial in AIPC cell proliferation and
survival [39]. Furthermore, the PI3K-Akt pathway is implicated in the
development and progression of AIPC in mice [42–44]. We have
reported that JNK is necessary for leptin-stimulated AIPC cell
proliferation [9]. In the present study we showed that JNK mediated
Fig. 10.Model of leptin signaling network that mediates AIPC cell proliferation. Leptin activates JNK and JAK upon binding to the leptin receptor. After STAT3 activation is triggered by
JAK-mediated Tyr-705 phosphorylation, JNK further stimulates and stabilizes STAT3 activation via Ser-727 phosphorylation. JNK also activates c-Jun through Ser-63 and -73
phosphorylation. Moreover, JNK mediates Akt activation through PI3K. Activation of these signaling pathways leads to expression of cell growth-relevant genes, resulting in
androgen-independent cell proliferation. Transcription factor(s) that form a complex with c-Jun are unknown in leptin-stimulated AIPC cells. Signaling molecules downstream of Akt
also need to be identiﬁed.
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and Akt (Fig. 9). To the best of our knowledge, this is the ﬁrst evidence
for interaction of these three oncogenic molecules in AIPC. Of interest,
JNK [54], STAT3 [55–57] and PI3K-Akt [58–60] all play a role in obesity,
too. Therefore, these molecules, as well as leptin, are mediators
between AIPC and obesity.
Constitutive STAT3 activation is critical in pathogenesis of many
types of cancer including AIPC [34,39,61]. Ser-727 phosphorylation is
involved in persistent activation of STAT3 [62]. Here we showed that
leptin augmented constitutive STAT3 activation through JNK-
mediated Ser-727 phosphorylation during AIPC cell proliferation
(Fig. 5). Our previous study has demonstrated that adipose cytokine
adiponectin, which decreases in obesity and competes with leptin to
suppress AIPC cell growth [23], inhibits constitutive STAT3 activation
[49]. These ﬁndings together suggest that STAT3 is a key signaling
determinant in adipose cytokine regulation of AIPC cell growth.
Furthermore, it has been reported that STAT3 activation via JNK-
mediated Ser-727 phosphorylation is required for Src oncoprotein-
induced malignant transformation [37]. Therefore, JNK-mediated
STAT3 activation appears to play a crucial role in both malignant
transformation and progression in cancer.
We demonstrated that JNK was indispensable for leptin-stimu-
lated rapid activation of Akt during AIPC cell proliferation in DU145
cells (Fig. 7). This is the ﬁrst evidence for the requirement of JNK for
Akt activation in cancer cells. Pharmacological inhibition of PI3K
suppressed leptin-stimulated Akt activation in DU145 cells (Fig. 6A),
indicating that PI3K is upstream of Akt in the leptin signaling. In
addition, PI3K inhibition did not suppress leptin-stimulated JNK
activation (data not shown). Therefore, JNK is most likely to be
upstream of PI3K to mediate leptin-stimulated Akt activation in
DU145 cells (Fig. 10). DU145 cells express wild-type PTEN [21].
Intriguingly, constitutively activated PI3K stimulates JNK activity in
PTEN-deﬁcient cells [63]. Thus, the JNK and PI3K pathways could
regulate each other; and PTEN status may determine which pathway
dictates the other. In vitro evidence for signaling interaction between
JNK and Akt agrees with positive correlation between phospho-c-Jun
and phospho-Akt in immunohistochemical staining of human
prostate cancer tissue [63].We showed that leptin stimulated activation of JNK-c-Jun, STAT3
and Akt in TRAMP-C1, as well as DU145, cells (Fig. 8). Furthermore, JNK
mediated leptin-stimulated STAT3 and Akt activation in both cell lines
(Fig. 9). These results suggest that leptin-induced activation/interac-
tion of these molecules is not a phenomenon speciﬁcally observed in a
certain cell line but a generally occurring event that mediates AIPC cell
growth. Therefore, co-activation states of JNK, STAT3 and Akt in tumor
cells may well predict and diagnose androgen-independent progres-
sion of prostate cancer; and disruption of their signaling interaction
could be therapeutic for AIPC.
In addition to the leptin signaling network demonstrated in this
study (Fig. 10), some other mechanisms may be involved in leptin
regulation of AIPC progression. Leptin stimulates PC-3 cell migration
through ERK activation [22]. Thus, ERKmaymediate leptin-stimulated
AIPC cell growth as well. Leptin is also known to up-regulate genes
encoding such growth factors as vascular endothelial growth factor,
transforming growth factor-β1 and basic ﬁbroblast growth factor [22].
Therefore, leptin may promote AIPC progression including tumor
growth, metastasis and angiogenesis via regulation of such genes.
Moreover, it is interesting to note that leptin stimulates expression of
the suppressor of cytokine signaling 3 (SOCS3) gene in AIPC cells [21],
as well as some other cell types and tissues [64–68]. SOCS3 inhibits
leptin signaling through acting on JAK [69,70] so that it may work as a
negative feedback mechanism for leptin-mediated AIPC progression.
Further investigation is needed to clarify the entire leptin signaling
network in AIPC.
In summary, adipose leptin mediates AIPC cell growth accelerated
by obesity. Leptin and its downstream signaling molecules JNK, STAT3
and Akt are molecular mediators between obesity and prostate cancer
and could be prognostic, diagnostic, therapeutic targets for AIPC.
Further studies are ongoing in our laboratory to conﬁrm this
hypothesis using mouse models and human subjects.
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